In last trading session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) saw 4.75 million shares changing hands with its beta currently measuring 1.16. Company’s recent per share price level of $1.35 trading at $0.06 or 4.65% at ring of the bell on the day assigns it a market valuation of $490.29M. That closing price of LXRX’s stock is at a discount of -81.48% from its 52-week high price of $2.45 and is indicating a premium of 79.26% from its 52-week low price of $0.28. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.27 million shares which gives us an average trading volume of 4.87 million if we extend that period to 3-months.
For Lexicon Pharmaceuticals Inc (LXRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Lexicon Pharmaceuticals Inc’s shares saw a change of -31.82% in year-to-date performance and have moved 19.47% in past 5-day. Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) showed a performance of 101.49% in past 30-days. Number of shares sold short was 37.56 million shares which calculate 9.39 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 77.5% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -344.44% in reaching the projected high whereas dropping to the targeted low would mean a loss of -344.44% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 49.60% while estimates for its earnings growth in next 5 years are of 30.30%.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Insiders are in possession of 1.17% of company’s total shares while institution are holding 74.93 percent of that, with stock having share float percentage of 75.82%. Investors also watch the number of corporate investors in a company very closely, which is 74.93% institutions for Lexicon Pharmaceuticals Inc that are currently holding shares of the company. ARTAL GROUP S.A. is the top institutional holder at LXRX for having 175.1 million shares of worth $294.17 million. And as of 2024-06-30, it was holding 56.3318 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 38.69 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.4462 of outstanding shares, having a total worth of $64.99 million.
On the other hand, Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of May 31, 2025 , the former fund manager was holding 11.05 shares of worth $14.92 million or 3.04% of the total outstanding shares. The later fund manager was in possession of 5.15 shares on Mar 31, 2025 , making its stake of worth around $6.95 million in the company or a holder of 1.42% of company’s stock.
